2025-05-21-Jefferies-维罗纳（VRNA）_2025年美国胸科学会会议额外的三期分析支持Ohtuvayre在慢性阻塞性肺疾病中的广泛应用案例_22页_3mb

报告摘要

Equity Research Summary: Verona Pharma (VRNA) - Ohtuvayre (Ensifentrine)

Company Overview: Verona Pharma (VRNA) is a clinical-stage biopharmaceutical company with ensifentrine (Ohtuvayre) approved for COPD by the FDA in June 2024. The drug is a novel PDE3/4 inhibitor delivered via a twice-daily nebulizer.
Key Findings:
- Phase III data show Ohtuvayre improves lung function (FEV1), reduces moderate/severe exacerbations (pbo-adj reductions: -36% to -40%), and enhances patient-reported outcomes like dyspnea and quality of life across various subgroups, including those with comorbid Type 2 diabetes (T2D) or cardiac disorders.
- Real-world data confirms that ICS-containing COPD therapies increase pneumonia risk (15-25% prevalence), suggesting Ohtuvayre could supplant these treatments due to its bronchodilator and anti-inflammatory properties.
- Preclinical IPF studies indicate competitive efficacy against Ofev (nintedanib), potentially supporting indication expansion to idiopathic pulmonary fibrosis or other respiratory conditions.
Analyst Recommendation: Buy with a price target of $95 (up 28% from current price), based on solid Phase III metrics, mgmt execution, and the drug's role as an add-on therapy for COPD. Jefferies analysts highlight no imminent slowdown in Ohtuvayre's development and commercialization.
Financial Projections:
- Current market cap: $6.2B. Expected revenue growth from $42.3M in 2024 to $650.0M by 2026, with peak sales potential of $2.5B-$3.5B.
- Upside scenario: 75% revenue increase; downside scenario: 60% decrease due to ramp risks.
Risks: Single-product focus, regulatory and competitive challenges, access/affordability concerns post-launch. The drug requires monitoring for product quality and safety in comorbid patient populations.
Market Opportunity: Ohtuvayre addresses an 8.5M+ US COPD patient market and could expand the $10B+ branded drug space, potentially shifting away from ICS use to reduce pneumonia risk.